NYSE:OGN Organon & Co. Q1 2026 Earnings Results & Report $13.78 +0.01 (+0.04%) Closing price 03:59 PM EasternExtended Trading$13.78 0.00 (0.00%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Organon & Co. missed analyst expectations on both earnings and revenue in its Q1 2026 results, released April 30, 2026. The company reported EPS of $0.71 versus the $0.83 consensus estimate, while revenue of $1.46 billion fell short of the $1.49 billion estimate by $27.54 million. Revenue decreased 3.5% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateApril 30, 2026TimeBefore Market OpensConference Call7:00 AM ET Organon & Co. EPS ResultsActual EPS$0.71Consensus EPS $0.83Beat/MissMissed by -$0.12One Year Ago EPS$1.02EPS Beat Rate4 of last 8 quartersOrganon & Co. Revenue ResultsActual Revenue$1.46 billionExpected Revenue$1.49 billionBeat/MissMissed by -$27.54 millionYoY Revenue Growth-3.50%Upcoming EarningsOrganon & Co.'s Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Organon & Co. Q1 2026 Earnings FAQ Did Organon & Co. beat earnings estimates for Q1 2026? Organon & Co. (NYSE:OGN) reported earnings of $0.71 per share for Q1 2026, missing the consensus estimate of $0.83. The report was announced on Thursday, April 30, 2026. What was Organon & Co.'s revenue for Q1 2026? Organon & Co. reported revenue of $1.46 billion for Q1 2026, against a consensus estimate of $1.49 billion. When is Organon & Co.'s next earnings date? Organon & Co.'s next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Organon & Co. on the company's earnings history page. Organon & Co. Earnings HeadlinesOrganon & Co stock hits 52-week high at 13.79 USDOctober 7, 2026 | investing.comOrganon Canada Announces Approval And Availability Of NDUVRA® (Tapinarof Cream), 1%, For Moderate To Severe Atopic Dermatitis In Adult and Pediatric Patients 2 Years Of Age ...September 28, 2026 | marketscreener.comMTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 13 at 1:00 AM | Porter & Company (Ad)Organon Says Nduvra Cream Gets Canada Approval for Atopic DermatitisSeptember 28, 2026 | marketscreener.comMOrganon Canada Gets Approval For NDUVRA 1% Non-Steroid Cream For Atopic DermatitisSeptember 28, 2026 | rttnews.comOrganon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult ...September 28, 2026 | marketscreener.comMSee More Organon & Co. Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Organon & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organon & Co. and other key companies, straight to your email. Email Address About Organon & Co.Organon & Co. (NYSE:OGN) is a global healthcare company focused primarily on women’s health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world. Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health. Organon also markets established brands in categories such as cardiovascular disease, respiratory health, dermatology, pain management and gastroenterology. Its biosimilars business provides lower-cost alternatives to certain biologic medicines and includes products developed through internal programs and commercial partnerships. Organon was established as an independent, publicly traded company in June 2021 after being separated from Merck & Co. The company is headquartered in Jersey City, New Jersey, and serves patients and healthcare providers across international markets through its commercial and manufacturing operations.View Organon & Co. ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
